Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235210 | 0.88 | MAPT (0.38) | MEN1NPC1ALDH1A1TP53MAPT | |
| SCHEMBL2241640 | 0.85 | — | — | |
| SCHEMBL2236059 | 0.85 | SLC9A1 (0.32) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL2385285 | 0.84 | GSK3B (0.39) | MEN1NPC1ALDH1A1TP53MAPT | |
| SCHEMBL2239872 | 0.81 | PTGS1 (0.42) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL2236712 | 0.81 | — | — | |
| SCHEMBL2234250 | 0.81 | ADORA2A (0.30) | — | |
| SCHEMBL2236714 | 0.79 | PTGS1 (0.40) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL2234742 | 0.78 | IKBKB (0.34) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL2238185 | 0.77 | NQO2 (0.31) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2360163-B1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | JAPAN POLYPROPYLENE CORP (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-8461365-B2 | Metallocene complex and polymerization method of olefin | JAPAN POLYPROPYLENE CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | JAPAN POLYPROPYLENE CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2360163-A1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | Japan Polypropylene Corporation (JP) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | ALOX12, ALOX15, ALOX15B | MEN1 1018/4885NPC1 1170/4885ALDH1A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.